A prospective observational study by Syversen et al. found that patients with immune-mediated inflammatory diseases (IMID) had an attenuated serologic response to the standard two-dose vaccine regimen but a third dose was safe and effective.
2023 Proposed Rule for the Quality Payment Program Released
The ACR RISE Registry staff highlights need-to-know information and key changes for the 2023 performance year as outlined in the proposed rule released July 7.
How to Connect with Your Members of Congress During the August Recess
Many members of Congress return to their home states and districts in August, making it a great time to engage them in local conversations about healthcare policies and how they affect rheumatology practices and patients.
The Rheumatologist Honored with Grand Award for Publication Excellence
We are honored to announce that The Rheumatologist has received a Grand Award for publication excellence from APEX 2022 for COVID-19: A Special Report, a supplement that mailed with the February 2021 issue of the magazine. The Annual Awards for Publication Excellence (APEX) are based on excellence in graphic design, editorial content and the ability…
Study Compares Intra-Articular Morphine with Steroids & Placebo in Patients with Chronic Knee Arthritis
A study from Haibel et al. in patients with chronic knee arthritis found intra-articular morphine did not lead to a significant, short-term reduction in pain compared with placebo and proved inferior to treatment with intra-articular triamcinolone.
FDA Approves Riabni, a Rituxumab Biosimilar, to Treat Patients with RA
Based on findings from a double-blind, placebo-controlled study evaluating its efficacy and safety, rituximab-arrx has received FDA approval for the treatment of patients with rheumatoid arthritis.
The ACR Responds to Impact of the Dobbs v. Jackson Decision on Rheumatology Patients and Providers
The ACR and a new Access to Reproductive Health Care Task Force are working to ensure patients with rheumatic disease—particularly women—have access to the medications and treatments they need, including methotrexate, and that rheumatology providers are able to maintain trusting relationships with and advise their patients on all matters relevant to the management of their rheumatic diseases.
CMS Releases CY23 Medicare Physician Fee Schedule & Quality Payment Program Updates
If enacted as is, the proposed CY 2023 Medicare Physician Fee Schedule and Quality Payment Program would make significant cuts to reimbursement for evaluation and management services, creating financial instability for providers. On a positive note, it would extend some telehealth flexibilities 151 days beyond the official end of the public health emergency.
Cigna Delays Modifier 25 Policy Change for Evaluation & Management Services
Cigna will not move forward with changes to their reimbursement policy for evaluation and management (E/M) codes submitted with modifier 25 as originally scheduled.
Applications Now Open for 2022 Advocates for Arthritis
All ACR and ARP members are invited to apply to join colleagues and patients in Washington, D.C., on Sept. 19–20 for advocacy training and meetings with legislators to advocate on priority issues that affect rheumatology providers and patients.
- « Previous Page
- 1
- …
- 42
- 43
- 44
- 45
- 46
- …
- 317
- Next Page »